1,987
Views
15
CrossRef citations to date
0
Altmetric
Correspondence

Safety issues associated with the use of angiotensin-converting enzyme inhibitors

Response to: BELTRAMI L, ZINGALE LC, CARUGO S, CICARDI M: Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin. Drug Saf. (2006) 5(5):643-649.

Pages 739-740 | Published online: 18 Oct 2006

Bibliography

  • BELTRAMI L, ZINGALE LC, CARUGO S, CICARDI M: Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. Expert Opin. Drug Saf. (2006) 5(5):643-649.
  • ADAM A, CUGNO M, MOLINARO G, PEREZ M, LAPAGE Y, AGOSTONI A: Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet (2002) 359(9323):2088-2089.
  • ACHARYA KR, STURROCK ED, RIORDAN JF, EHLERS MRW: ACE revisited: a new target for structure-based drug design. Nat. Rev. Drug Disc. (2003) 2(11):891-902.
  • NATESH R, SCHWAGER SL, STURROCK ED, ACHARYA KR: Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature (2003) 421(6922):551-554.
  • CORRADI HR, SCHWAGER SL, NCHINDA AT, STURROCK ED, ACHARYA KR: Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J. Mol. Biol. (2006) 357(3):964-974.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.